Skip to content

Pipeline

Our Pipeline

We’re aligning our investments in scientific research, manufacturing and commercialization to change the way cancer, eye and autoimmune diseases are treated.
Molecule
Mechanism
Disease State
Development Stage
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Development Stage
Phase 3 Ongoing
Pivotal Trial
RC18
Fusion protein
BLyS/APRIL
Phase 3 Ongoing Pivotal Trial
Rheumatoid Arthritis (RA)
Rhematoid arthritis (RA) is an autoimmune disease in which the immune system attacks the joints, leading to swelling and pain in and around joints Approximately, 1% of the world’s population lives with RA, with at least twice as many women affected as men. Experts predict the number of patients with RA may double by 2030 as the global population gets older.

The current standard of care for rheumatoid arthritis has been steroids and subcutaneous biologics. RemeGen is currently testing a fusion protein candidate, RC18 in patients with rheumatoid arthritis.
Sources: Arthritis Foundation. Arthritis by the numbers: book of trusted facts and figures. 2018; v2; 4100.17.10445.
World Health Organisation, The Global Burden of Disease Report, (table 7, page 32) 2004,
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Development Stage
Phase 3 Ongoing
Pivotal Trial
RC18
Fusion protein
BLyS/APRIL
Phase 3 Ongoing Pivotal Trial
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis optica spectrum disorder (NMOSD), is an autoimmune disease in which the myelin sheath that protect nerves is attacked by the immune system over time, leading to neurological symptoms similar to those of multiple sclerosis. NMOSD is a rare disease with low prevalence, affecting about 0.0004% of the world’s population

The current standard of care for NMOSD is systemic steroids. RemeGen is currently testing a fusion protein candidate, RC18, in patients with NMOSD.
Source: Marrie RA and Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care. 2013;15(3): 113–118.
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Development Stage
Phase 2 Complete
Pivotal Trial
RC18
Fusion protein
BLyS/APRIL
Phase 2 Complete Pivotal Trial
System Lupus Erythematosus (SLE)
System lupus erythematosus (SLE), or lupus, is a chronic autoimmune disease in which the immune system attacks healthy tissue in many parts of the body, including the joints, skin, kidneys, blood cells, brain, heart, and lungs. About 5 million people around the world are affected by lupus, with about 16,000 new cases reported each year.

The current standard of care for lupus is systemic steroids, as there has only been a single lupus drug approved in the last 60 years. RemeGen is currently testing a fusion protein candidate, RC18, in patients with lupus.
See latest data
Source: Lupus Foundation of America.
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Disease State
Multiple
Scierosis
Development Stage
Phase 2
RC18
Fusion protein
BLyS/APRIL
Multiple
Scierosis
Phase 2
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Disease State
IgA
Nephritis
Development Stage
Phase 2
RC18
Fusion protein
BLyS/APRIL
IgA
Nephritis
Phase 2
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Disease State
Gravis
Development Stage
Phase 2
RC18
Fusion protein
BLyS/APRIL
Gravis
Phase 2
Molecule
RC18
Mechanism
Fusion protein
BLyS/APRIL
Disease State
Sjogren’s
Syndrome
Development Stage
Phase 2
RC18
Fusion protein
BLyS/APRIL
Sjogren’s
Syndrome
Phase 2
Molecule
Mechanism
Disease State
Development Stage
Molecule
RC48
Mechanism
ADC
HER2
Disease State
Gastric
Cancer
Development Stage
Phase 2 Complete
Pivotal Trial
RC48
ADC
HER2
Phase 2 Complete Pivotal Trial
Gastric Cancer
Gastric cancer is the 4th most common cancer in the world, with the majority of patients presenting with inoperable and/or advanced cases. Up to 22% of gastric cancers are caused by a mutation in the HER2 gene; A HER2+ mutation in gastric cancer generally suggests a poorer prognosis for the patient.

The current standard of care for HER2+ gastric cancers is combination chemotherapy and palliative care. RemeGen is currently testing our anti-HER2 antibody-drug conjugate candidate, RC48, in patients with HER2+ gastric cancer.
See latest data
Source: Kang et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Brit J Cancer. 2014;111:660-666.
Molecule
RC48
Mechanism
ADC
HER2
Disease State
Urothelial
Cancer
Development Stage
Phase 2 Complete
Pivotal Trial
RC48
ADC
HER2
Phase 2 Complete Pivotal Trial
Urothelial Cancer
Urothelial carcinoma is a common cancer worldwide. Bladder cancer being the most common subtype, with a projected 540,000 new cases and ~200,000 deaths in 2018. Of cancer types with the HER2+ mutation, urothelial cancers are the 3rd most prevalent.

The current standard of care for HER2+ urothelial cancers is chemotherapy. RemeGen is currently testing our anti-HER2 antibody-drug conjugate candidate, RC48, in patients with HER2+ urothelial cancer.
See latest data
Source: World Health Organization. Globocan 2018.
Molecule
RC48
Mechanism
ADC
HER2
Disease State
Breast
Cancer
Development Stage
Phase 2 Complete
RC48
ADC
HER2
Breast
Cancer
Phase 2 Complete
Molecule
RC48
Mechanism
ADC
HER2
Disease State
Lung
Cancer
Development Stage
Phase 1
RC48
ADC
HER2
Lung
Cancer
Phase 1
Molecule
RC48
Mechanism
ADC
HER2
Disease State
Bile duct
Cancer
Development Stage
Phase 1
RC48
ADC
HER2
Bile duct
Cancer
Phase 1
Molecule
Mechanism
Disease State
Development Stage
Molecule
RC28
Mechanism
Fusion protein
VEGF/FGF
Disease State
wAMD
Development Stage
Phase 1 Complete
RC28
Fusion protein
VEGF/FGF
wAMD
Phase 1 Complete
Molecule
RC28
Mechanism
Fusion protein
VEGF/FGF
Disease State
Diabetic Macular
Edema
Development Stage
Phase 1
RC28
Fusion protein
VEGF/FGF
Diabetic Macular
Edema
Phase 1
Molecule
Mechanism
Disease State
Development Stage
Molecule
RC88
Mechanism
ADC
Mesothelin
Disease State
Multiple Solid
Cancer
Development Stage
Phase 1
RC88
ADC
Mesothelin
Multiple Solid
Cancer
Phase 1
Molecule
Mechanism
Disease State
Development Stage
Molecule
RC98
Mechanism
mAb
PD-L1
Disease State
Multiple Solid
Cancer
Development Stage
IND
complete
RC98
mAb
PD-L1
Multiple Solid
Cancer
IND complete